MedPath

Comparison of SEPTal and Apical Pacing Sites in PerManent Right Ventricular Pacing

Phase 3
Completed
Conditions
Atrioventricular Block
Interventions
Device: RV lead
Registration Number
NCT00925691
Lead Sponsor
Rennes University Hospital
Brief Summary

The SEPTAL-PM study is aimed to compare the right ventricular apical and right ventricular septal position of the right ventricular lead in patients implanted with a pacemaker for conventional anti-bradycardia pacing indications requiring permanent right ventricular pacing ; the primary endpoint is the evolution of the left ventricular ejection fraction assessed by contrast echocardiography at 18-months follow-up.

Detailed Description

Classically the right ventricular pacing (RV) lead position is the RV apex. Several small studies suggested that the septal position which provided a more physiological conduction pattern would improve left ventricular function and dimensions and the patients' outcome.

The SEPTAL-PM study is a parallel randomized prospective simple-blinded and multicenter national study with a follow-up duration of 18 month. A total of 180 patients will be enrolled.

It was designed to demonstrate that in patients requiring permanent RV pacing for high degree atrio-ventricular conduction disorders the septal pacing would preserve the LVEF and LV dimensions but also the quality of life and the exercise tolerance.

The primary endpoint is the evolution of the LVEF assessed by contrast echocardiography. The secondary endpoints are: the quality of life SF 36 questionnaire, the NYHA class, the 6-minute-walk test, the QRS duration, the LV end-systolic and diastolic volumes, the NT-pro BNP, MMP 2-9 and TIMP-1 dosages, stimulation and detection ventricular thresholds.

Other reported parameters are: the probes position and electric parameters, all causes of mortality, cardiovascular mortality, hospitalisations for cardiovascular causes, serious adverse events.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
141
Inclusion Criteria
  • Age over 18 years old.
  • Written informed consent.
  • Permanent cardiac pacing indication for high degree AV block with ventricular rate less than 50 bpm according to the current guidelines of the European Society of Cardiology .
  • Patients with sinus rhythm or permanent atrial fibrillation.

Non-inclusion Criteria:

  • Indication for cardiac resynchronization.
  • Indication for Intra cardiac defibrillators (ICD).
  • Indication for AV node ablation for patients with atrial fibrillation.
  • Patients already implanted with a pacemaker or an ICD.
  • Myocardial infarction within the previous month.
  • Surgically treated valvulopathy.
  • Tricuspid Valve prothesis
  • Cardiac surgery or coronary revascularization planned or within the 3 last months.
  • Life expectancy less than 18 months.
  • Pregnancy.
  • Disability to give informed consent.
Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
APICALRV leadimplantation at the apex
SEPTALRV leadimplantation at the interventricular septum
Primary Outcome Measures
NameTimeMethod
Left ventricular ejection fraction18 months
Secondary Outcome Measures
NameTimeMethod
Serious adverse events18 months
Quality of life questionnaire SF 3618 months
NYHA class1, 6, 12, 18 months
6-minute-walk test1, 18 months
Evolution of cardiac remodeling markers: MMP2-9 and TIMP-1 and NT-pro BNP dosage18 months
LV end-systolic and diastolic volumes18 months
QRS duration,1, 6, 12, 18 months
All causes and cardiovascular mortality, hospitalizations for cardiovascular cause18 months
Stimulation and detection ventricular thresholds1, 6, 12, 18 months
Probes position and electric parameters18 months

Trial Locations

Locations (5)

CHU d'Angers

πŸ‡«πŸ‡·

Angers, France

CHU de Poitiers

πŸ‡«πŸ‡·

Poitiers, France

Service de cardiologie-CHU de Brest

πŸ‡«πŸ‡·

Brest, France

CHU de Rennes

πŸ‡«πŸ‡·

Rennes, France

Service de cardiologie-CHU de Nantes

πŸ‡«πŸ‡·

Nantes, France

Β© Copyright 2025. All Rights Reserved by MedPath